 ISELIN, N.J., Aug. 03, 2021 GLOBE NEWSWIRE -- Outlook Therapeutics, Inc. Nasdaq: OTLK, a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 LYTENAVATM bevacizumab for treatment of neovascular age-related macular degeneration wet AMD. Outlook Therapeutics will host a conference call and webcast today, August 3, 2021, at 8:00 a.m. ET details below to discuss the results of the study. 